Talphera Inc.
TLPH
Get informed when a big investor buys or sells
+ FollowMarket Cap$60.2M
Close$
$-0.01
101.3% downside
Current Fair Value
101.3% downsideOvervalued by 101.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $60.20 Million |
|---|---|
| Enterprise Value | $59.46 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.34 |
| Beta | 0.69 |
| Outstanding Shares | 75,526,900 |
Return
| Return on Equity | -104.65% |
|---|---|
| Return on Assets | -56.24% |
| Return on Invested Capital | -67.21% |
Valuation & Multiples
| P/E Ratio | -3.63 |
|---|---|
| PEG | -15.41 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 59461.54 |
| Enterprise Value to EBIT | -3.91 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.8784▼ 27.72% |
|---|---|
| Total Calls | 100,300▲ 6.14% |
| Total Puts | 88,100▼ 19.32% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 31.60%▼ 19.96% |
|---|---|
| Total Invested | $24.59M▲ 50.54% |
| Investors Holding | 55▲ 4.00% |
ESG Score
No data
About Talphera Inc.
31,000 employees
CEO: Vincent Angotti acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (kno...